+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB)



Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB)



Thrombosis Research 28(1): 75-83



The association of viral hepatitis, type B, with the use of prothrombin complex concentrates (PPSB) has been well documented. PPSB prepared from cold-sterilized plasma (beta-propiolactone treated and UV irradiated) has been shown not to induce hepatitis in chimpanzees. 500 U of cold-sterilized PPSB were infused into 5 healthy male volunteers. Previous to, and up to 6 months after, PPSB-application in addition to careful clinical investigations, the following hepatitis parameters were determined: SGOT, SGPT, y-GT, alkaline phosphatase, total serum bilirubin, HBsAg, HBcAb and HBsAb. On the basis of all of the above parameters there was no indication of induction of viral hepatitis following the application of PPSB prepared from beta-propiolactone/UV treated plasma.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 042563360

Download citation: RISBibTeXText

PMID: 7157232


Related references

Safety of beta propiolactone uv treated ppsb factor ix concentrate. Thrombosis Research (Suppl. 7): 49, 1987

Evaluation of thrombogenicity of beta-propiolactone/ultraviolet (beta-PL/UV) treated PPSB in chimpanzees. Thrombosis Research 30(3): 235-244, 1983

Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees. Thrombosis and Haemostasis 46(2): 511-514, 1981

Clinical evaluation of the hepatitis safety of a beta propio lactone uv treated factor ix concentrate. Thrombosis Research 28(1): 75-84, 1982

Beta-Propiolactone Plus Ultraviolet Irradiated Plasma. a Clinical Evaluation for Hepatitis, Toxicity and Allergy. Bibliotheca Haematologica 19: 644-647, 1964

Beta-propiolactone plus ultraviolet irradiated plasma. A clinical evaluation for hepatitis, toxicity and allergy. Proc Congr Int Soc Blood Transfus 9: 644-647, 1962

Biotest position on HIV-1 seroconversions in 1990 in 11 patients, treated with beta-propiolactone/uv virus inactivated PPSB. Infusionstherapie und Transfusionsmedizin 20(6): 344-346, 1993

Human Plasma Treated with Ultraviolet and Propiolactone. Six-Year Clinical Evaluation. JAMA 187: 722-726, 1964

A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin. Arzneimittel-Forschung 31(11): 1928-1930, 1981

Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences. Developments in Biological Standardization 67: 311-317, 1987

Preparation and clinical use of factor IX concentrate PPSB according to Soulier. Vox Sanguinis 16(4): 398-411, 1969

Evaluation of thrombogenicity of beta propiolactone uv treated prothrombin proconvertin stuart factor antihemophilic factor b in rabbits. Blut 49(2): 147-148, 1984

Propiolactone plus ultraviolet-treated plasma without hepatitis. Arch Surg 88(4): 721-724, 1964

Serum hepatitis and the clinical evaluation of blood components sterilized with beta-propiolactone. Bibliotheca Haematologica 13: 504-509, 1962

The safety of beta-propiolactone as a biologic sterilizing agent. Clinical evaluation with human plasma and homotransplants. Angiology 12: 80-83, 1961